Ductal Carcinoma In Situ (DCIS): Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Ductal carcinoma in situ (DCIS) is a non-invasive breast neoplasm in which malignant epithelial cells are confined within breast ducts without invasion through the basement membrane into surrounding stroma. DCIS accounts for approximately 20–25% of newly diagnosed breast cancers in the US, representing approximately 50,000 cases per year, detected almost exclusively by mammographic screening as microcalcifications. DCIS is classified by nuclear grade (low, intermediate, or high) and by the presence or absence of comedonecrosis. High-grade DCIS with comedonecrosis has a higher risk of progression to invasive breast cancer and local recurrence after treatment. ER/PR status and HER2 expression are reported. DCIS has an excellent disease-specific survival exceeding 98% at 10 years when treated appropriately. The management challenge is that some DCIS, particularly low-grade ER-positive lesions, may never progress to invasive cancer during a patient's lifetime, prompting ongoing active surveillance trials (COMET, LORD).

Risk factors for DCIS parallel those of invasive breast cancer. Age is the most important factor, with peak incidence between 50–59 years coinciding with widespread mammographic screening. Family history of breast cancer in a first-degree relative approximately doubles risk. BRCA1/2 germline mutations confer a lifetime DCIS risk of 40–60%, with earlier age of onset. Prior breast biopsy showing atypical ductal hyperplasia (ADH) increases relative risk approximately 4–5-fold. Additional risks include dense breast tissue on mammography, nulliparity, late menopause, obesity (postmenopause), and prolonged combined (estrogen-progestogen) hormone replacement therapy. DCIS and invasive breast cancer share overlapping molecular pathways, and high-grade DCIS frequently harbors HER2 amplification and TP53 mutations.

The vast majority of DCIS — approximately 80–90% — is completely asymptomatic and detected only on routine screening mammography as clustered microcalcifications (often fine linear, branching, or pleomorphic in morphology), architectural distortion, or soft tissue asymmetry. Symptomatic presentations, now uncommon in the modern screening era, include a palpable breast lump (particularly in high-grade or comedonecrosis DCIS), bloody or serous nipple discharge without associated lump, or Paget's disease of the nipple — an eczematous, scaling, or crusting change of the nipple-areola complex representing DCIS of the large subareolar ducts. Skin retraction or dimpling is rare and suggests deep involvement near the skin ligaments.

Diagnostic mammography characterizes calcification morphology and distribution (segmental or linear distributions have higher malignant potential). Breast ultrasound evaluates associated mass lesions or duct dilatation. Breast MRI is used for extent assessment and evaluation of the contralateral breast, though its higher false-positive rate limits routine use. Stereotactic vacuum-assisted core needle biopsy under mammographic guidance is the standard tissue acquisition method. Pathology report should include nuclear grade, presence of comedonecrosis, ER/PR and HER2 receptor status, and surgical margin status. Van Nuys Prognostic Index (VNPI) incorporates size, margin width, nuclear grade, and age to estimate recurrence risk. Genomic testing (Oncotype DX DCIS Score) helps predict 10-year local recurrence risk in ER-positive patients considering lumpectomy without radiation.

Breast-conserving surgery (lumpectomy) plus adjuvant whole-breast irradiation (40–50 Gy in 15–25 fractions, or accelerated 26 Gy in 5 fractions) is the standard of care, reducing 10-year local recurrence from approximately 25–30% to 10–15%. Accelerated partial breast irradiation (APBI) is an alternative for selected low-risk patients. Total mastectomy (local recurrence under 1%) is appropriate for multicentric or diffuse DCIS, BRCA1/2 carriers, patients with extensive microcalcifications, or those unable to receive radiotherapy. Endocrine therapy for ER-positive DCIS: tamoxifen 20 mg daily for 5 years (premenopausal/postmenopausal) or anastrozole/letrozole (postmenopausal, IBIS-II trial, superior to tamoxifen for ipsilateral and contralateral breast cancer risk reduction). Active surveillance is being investigated in low-risk low-grade ER-positive DCIS through the COMET and LORD randomized trials, with results pending.

Disease-specific survival exceeds 98% at 10 years — DCIS has an excellent prognosis when appropriately treated. After lumpectomy plus radiotherapy, 10-year local recurrence risk is approximately 10–15%; approximately half of local recurrences are invasive breast cancer. After mastectomy, local recurrence is under 1%. Low-grade ER-positive DCIS has a very low invasive progression risk over 10 years. High-grade DCIS with comedonecrosis carries a higher risk of both local recurrence and invasive progression. Endocrine therapy reduces ipsilateral events by approximately 40–50% and also reduces contralateral breast cancer. The prognosis for Ductal Carcinoma In Situ (DCIS): Causes, Symptoms, Diagnosis and Treatment varies depending on severity at diagnosis, the patient's overall health, and how promptly treatment is initiated. With early diagnosis and appropriate management, many patients achieve good outcomes and maintain quality of life. Regular follow-up with healthcare providers is essential to monitor progress, adjust treatment as needed, and detect any complications early. Adherence to prescribed treatments and lifestyle modifications significantly improves long-term prognosis.

Annual mammographic screening beginning at age 40 (American Cancer Society) or 45–50 (USPSTF) is the primary strategy for early DCIS detection. Women with dense breast tissue, personal or family history of breast cancer, or BRCA1/2 mutations should discuss supplemental screening with breast MRI with their physician. Chemoprevention with tamoxifen or aromatase inhibitors reduces the risk of ER-positive DCIS and invasive breast cancer by approximately 40–50% in high-risk women (those with atypical hyperplasia or lobular carcinoma in situ). BRCA1/2 mutation carriers may consider risk-reducing bilateral mastectomy. Lifestyle modifications — weight management, alcohol limitation, and avoiding extended combined HRT — offer modest risk reduction. Women with a history of DCIS require lifelong annual mammographic surveillance of any remaining breast tissue.

Schedule prompt evaluation with your physician or breast specialist if you notice any nipple discharge, particularly blood-stained or serous fluid from a single duct, which may represent DCIS of the central ducts. A new, painless breast lump, skin dimpling, nipple retraction, or any eczematous change of the nipple-areola complex (scaling, crusting, redness) that persists for more than 4 weeks should be evaluated urgently — this may represent Paget's disease of the nipple. All women aged 40 and older should maintain routine mammographic screening; mammography recall for additional views or biopsy of an abnormality should not be delayed. Women with known DCIS on surveillance should notify their breast surgeon of any new breast symptoms between scheduled imaging appointments without waiting for the next routine visit.